DOCSLIB.ORG

Entourage Effect”

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Entourage Effect” THE “ENTOURAGE EFFECT” The bioactive compounds of plants can be divided into three main categories: Terpens and terpenoids, with around 25.000 types; alkaloids, with about 12.000 types and phenolic compounds with approximately 800 types. As we said before, the cannabis plant is thought to have more than 500 compounds of which cannabinoids make up just around a hundred. So, what else is there in it that might be participating in the biological effects? Well, at the moment, two kinds of substances are being considered as having a role in what has been called “the entourage effect”, to describe the enhancement efficacy that is, improving the overall therapeutic effectiveness of the cannabinoids. These substances are the terpens and terpenoids, which give the plants they are in the flavor and fragrance or aroma. They are essential oils, volatile compounds that have been designated by the FDA as GRAS: Generally Recognized As Safe, they are potent and affect animal and human behavior when inhaled in very low concentrations, they are relaxant, anxiolytic, sedative, antimicrobial and antioxidants, and produce synergy with the analgesic and anti inflammatory effects of the cannabinnoids through the implementation of neurotransmitters like Serotonin, Dopamine, Nor adrenaline and GABA, and can interact also with the cannabinoid receptors acting either as modulators of the intoxicating effect of the psychotropic cananbinoid THC as is the case with the terpene beta-Caryophyllene,found in basil, black pepper, cinnamon leaves, and because of this effect, the therapeutic index of THC is increased; but also augmenting the psychoactive effect like with Myrcene, the most abundant terpene in the cannabis plant and found also in wild thyme, eucalyptus, citreous fruits, hops oil lemon grass and other plants. Other terpens include Pinene, Limonene, Linalool and many others that are all the subject of intense investigation. The other kind of compounds present in the Cannabis are the Flavonoids, which are a very well known nutrients group with 6.000 families identified of which 20 are present in the Cannabis. Some of these flavonoids are Quercetin, Cannflavin A, and Cannflavin B, this one found only in cannabis, beta-sitosterol, vipexin, and others. As we all know, flavonids are known for their antioxidant properties and for their vivid color. In a recent study by members of my Society, SEIC, it has been shown how the antitumor effect of THC in all three types of breast cancer, was bigger when an extract of the plant was used compared to just the THC molecule alone. The National Academy of Sciences, titled its 2017 report The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, and admitted that the report was made based only on studies conducted with FDA approved pharmaceuticals and among its final recommendations it stated that patients were not using the Cannabis in that way , but in many other forms of presentations, like oils, edibles and other concentrates, and thus concluded that this issue should be addressed in the near future. What we call now as “Full spectrum” oil is thus, the oil that has been minimally processed after its extraction and contains all the cannabinoids and as many terpenes and flavonoids as the extraction process has allowed for. This is also the reason why we should all ask to see the laboratory analytical test of the cannabis oil that we want to use, so that we can see all the information of the cannabinoids and terpens content. Copyright Dr. Cedro .
Load more

Recommended publications
  • Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning
    6 Clearing the Smoke on Cannabis Regular Use and Cognitive Functioning Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Amy Porath, Ph.D., Director, Research, CCSA Key Points • Regular use refers to weekly or more frequent cannabis use over a period of months to years. Regular cannabis use is associated with mild cognitive difficulties, which are typically not apparent following about one month of abstinence. Heavy (daily) and long-term cannabis use is related to more This is the first in a series of reports noticeable cognitive impairment. that reviews the effects of cannabis • Cannabis use beginning prior to the age of 16 or 17 is one of the strongest use on various aspects of human predictors of cognitive impairment. However, it is unclear which comes functioning and development. This first — whether cognitive impairment leads to early onset cannabis use or report on the effects of chronic whether beginning cannabis use early in life causes a progressive decline in cannabis use on cognitive functioning cognitive abilities. provides an update of a previous report • Regular cannabis use is associated with altered brain structure and function. with new research findings that validate Once again, it is currently unclear whether chronic cannabis exposure and extend our current understanding directly leads to brain changes or whether differences in brain structure of this issue. Other reports in this precede the onset of chronic cannabis use. series address the link between chronic • Individuals with reduced executive function and maladaptive (risky and cannabis use and mental health, the impulsive) decision making are more likely to develop problematic cannabis use and cannabis use disorder.
    [Show full text]
  • Extracts and Tinctures of Cannabis
    WHO Expert Committee on Drug Dependence Critical Review …………….. Extracts and tinctures of cannabis This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • Bill Analysis and Fiscal Impact Statement
    The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT (This document is based on the provisions contained in the legislation as of the latest date listed below.) Prepared By: The Professional Staff of the Committee on Agriculture BILL: SB 1766 INTRODUCER: Senator Powell SUBJECT: Sale of Hemp-derived Delta-8-tetrahydrocannabinol DATE: March 16, 2021 REVISED: ANALYST STAFF DIRECTOR REFERENCE ACTION 1. Becker Becker AG Pre-meeting 2. CJ 3. RC I. Summary: SB 1788 creates s. 581.218, F.S., to regulate the sale of hemp-derived delta-8- tetrahydrocannabinol (delta-8-THC) products. It provides definitions for certain terms relating to the sale of delta-8-THC products. The bill specifies that a sale of hemp-derived dela-8-THC products constitutes a delivery sale regardless of whether the person accepting the order for the delivery is located in Florida. A retailer who mails or ships any hemp-derived delta-8-THC products must: Obtain a certification from the consumer who is purchasing the product that he or she is 21 years of age or older; Include as part of the order’s shipping documents, in a clear and conspicuous manner, the following statement: “Hemp-derived Delta-8-Tetrahydrocannabinol Products: Florida law prohibits shipping to individuals under 21 years of age and requires the payment of all applicable taxes”; and Be in compliance with any labeling requirements, pursuant to Department of Agriculture and Consumer Services rule for the state hemp program. The bill outlines specific violations that are misdemeanors of the first degree. The bill is effective July 1, 2021 BILL: SB 1766 Page 2 II.
    [Show full text]
  • The Entourage Effect of Whole-Plant Medicine
    CANN BIS THE ENTOURAGE EFFECT OF Whole-Plant, WHOLE-PLANT MEDICINE Whole Medicine BY DEBORAH PARKER WONG ithin the last decade, scientists have dis- as well as the less-known such as CBDV, a proven covered hundreds of biologically active anti-epileptic. W nutrients called phytochemicals, which are Food and health researchers have long concluded found in whole, unprocessed foods. There’s pteros- that while our bodies readily absorb these kinds of tilbene, a powerful antioxidant found in almonds, nutrients from whole foods, our ability to absorb syn- blueberries and Pinot Noir grapes that enables cells thetic, isolated supplements is limited at best. That’s exactly what cannabis researchers at the Hebrew University of Jerusalem discovered when comparing the efficacy of whole-plant cannabinoid (CBD) ex- tracts with synthetic, single-molecule CBDs. As the pharmaceutical industry rushes to market synthetic CBDs, research points to what’s called the “Entourage Effect,” wherein compounds work- ing together synergistically in whole-plant medi- cines amplify the overall effects and benefits of the medicine. When comparing synthetic CBDs with whole-plant extract, the Israeli researchers ob- served a narrow therapeutic window that limits the to break down fat and cholesterol; compounds like usefulness of the synthetic form and a far greater lycopene, which colors tomatoes red, and antho- range of effectiveness for CBD-rich, whole-plant cycanin, which gives berries of all kinds their deep extract. This, combined with the Entourage Effect, hues of blue. And of course, there’s the exciting makes whole-plant CBD extracts more effective at world of phytocannabinoids, cannabis-derived com- lower doses, with fewer adverse side effects, mak- pounds including the famously psychoactive THC, ing it ideal for clinical use.
    [Show full text]
  • Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model
    Glaucoma Harnessing the Endocannabinoid 2-Arachidonoylglycerol to Lower Intraocular Pressure in a Murine Model Sally Miller,1 Emma Leishman,1 Sherry Shujung Hu,2 Alhasan Elghouche,1 Laura Daily,1 Natalia Murataeva,1 Heather Bradshaw,1 and Alex Straiker1 1Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, United States 2Department of Psychology, National Cheng Kung University, Tainan, Taiwan Correspondence: Alex Straiker, De- PURPOSE. Cannabinoids, such as D9-THC, act through an endogenous signaling system in the partment of Psychological and Brain vertebrate eye that reduces IOP via CB1 receptors. Endogenous cannabinoid (eCB) ligand, 2- Sciences, Indiana University, Bloom- arachidonoyl glycerol (2-AG), likewise activates CB1 and is metabolized by monoacylglycerol ington, IN 47405, USA; lipase (MAGL). We investigated ocular 2-AG and its regulation by MAGL and the therapeutic [email protected]. potential of harnessing eCBs to lower IOP. Submitted: February 16, 2016 Accepted: May 16, 2016 METHODS. We tested the effect of topical application of 2-AG and MAGL blockers in normotensive mice and examined changes in eCB-related lipid species in the eyes and spinal Citation: Miller S, Leishman E, Hu SS, cord of MAGL knockout (MAGLÀ/À) mice using high performance liquid chromatography/ et al. Harnessing the endocannabinoid tandem mass spectrometry (HPLC/MS/MS). We also examined the protein distribution of 2-arachidonoylglycerol to lower intra- ocular pressure in a murine model. MAGL in the mouse anterior chamber. Invest Ophthalmol Vis Sci. RESULTS. 2-Arachidonoyl glycerol reliably lowered IOP in a CB1- and concentration-dependent 2016;57:3287–3296. DOI:10.1167/ manner. Monoacylglycerol lipase is expressed prominently in nonpigmented ciliary iovs.16-19356 epithelium.
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • Synthetic Cannabis
    Global emergence of synthetic cannabinoids Source: https://www.unodc.org/LSS/SubstanceGroup/Details/ae45ce06-6d33-4f5f-916a- e873f07bde02 Source: UNODC questionnaire on NPS, 2012 Background The appearance of ‘herbal highs’ in the market is not a new phenomenon. Such products usually consisted of plant mixtures with little psychoactive effects. Since 2004, however, the composition of these herbal products seems to have substantially changed to include potent new psychoactive compounds known as synthetic cannabinoids. Research on the mechanism of cannabis activity dates back several decades when molecules with similar behaviour to Δ9-tetrahydrocannabinol (THC) were first examined. A synthetic analogue of THC , ‘HU-210’, was first synthesized in Israel in 1988[1]and is considered to have a potency of at least 100 times more than THC. Due to its similar chemical structure to THC, ‘HU-210’ is regarded as a ‘classical cannabinoid’ and has been found in synthetic cannabinoids sold in the United States and other countries. Non-classical cannabinoids include cyclohexylphenols or 3-arylcyclohexanols (‘CP’compounds). ‘CP’ compounds were developed as potential analgesics by a pharmaceutical company in the 1980s. Respondents to the UNODC questionnaire on NPS have reported the emergence of CP-47,497 and CP-47,497-C8 in numerous countries in all regions except Africa since 2009. Other structurally dissimilar varieties of synthetic cannabinoids unrelated to THC have also emerged on the market. These include aminoalkylindoles, such as naphthoylindoles (e.g. JWH-018), phenylacetylindoles (e.g. JWH-250), and benzoylindoles (e.g. AM-2233).[2] JWH-018, arguably the most widely known synthetic cannabinoid, belongs to the group of aminoalkylindoles and is considered to be three times as potent as THC.
    [Show full text]
  • Therapeutic Aspects of Cannabis and Cannabinoids
    BRITISH JOURNAL OF PSYCHIATRY %2001), 178, 107^115 Therapeutic aspects of cannabis and cannabinoids{{ gave it to patients and was impressed with its muscle-relaxant, anticonvulsant and analgesic properties, and recorded its use- PHILIP ROBSON fulness as an anti-emetic. After these observations were published in 1842, medicinal use of cannabis ex- panded rapidly.It soon became available `over the counter' in pharmacies and by 1854 it had found its way into the United States Dispensatory.The American market became flooded with dozens of cannabis- containing home remedies. Background Review commissioned in In 1996 I was commissioned by the Depart- Queen Victoria's personal physician 1996 by the DepartmentofDepartment of Health ment of Health DOH) to review the wrote Reynolds, 1890), on the basis of scientific literature regarding the potential more than 30 years' experience, that DOH). therapeutic utility of cannabis and its ``Indian hemp, when pure and administered Aims Assess therapeutic profile of derivatives.The review was based upon carefully, is one of the most valuable primary sources identified from a Medline medicines we possess''.He found it incom- cannabis and cannabinoids. literature search, reference lists supplied by parable for ``senile insomnia'', ``night MethodMethod Medline search, references the DOH and the Institute for the Study of restlessness'' and ``temper disease'' in both Drug Dependence, and personal communi- children and adults, but not helpful in supplied by DOH and others, and cations with relevant academics
    [Show full text]
  • Cannabis Indica
    Basic Information of Cannabis Chatchada Bodhibukkana, Ph.D. R&D Institute, GPO Plant Type sativa indica ruderalis Ref : https://smoke.io/strains/@jwolf/the-clear-difference-between-cannabis-sativa-indica-and-ruderalis-or-simple-photos2 Plant Type - Origin Sativa Indica Ruderalis Tropical zone, which is The dry regions with little rainfall; The Asian parts of Russia. characterized by its warm and Afghanistan, Lebanon, and the Difference in daylengths. humid climate. Hindu Kush. (approx. 19 hours of daylight in It is located 23.5 degrees above Central Asia summer & 10.5 hours of daylight and below the equator. in winter) Small difference in daylengths. (approx. 13.5 hours of daylight in Short vegetative phase (growth summer & 10.5 hours of daylight phase). in winter) Automatically switches to the flowering phase (floral phase) regardless of the season. Ref : https://www.mallorca-seeds.com/difference-sativa-indica-ruderalis/ 3 Plant Type - Origin สายพันธ์ไทย-> sativa Ref : https://smoke.io/strains/@jwolf/the-clear-difference-between-cannabis-sativa-indica-and-ruderalis-or-simple-photos4 Sativa Vs Indica Ref: https://wisetoast.com/types-of-marijuana-and-effects Ref : https://www.cannaconnection.com/blog/11392-difference-indica-sativa-ruderalis-hybrid-plants 5 Ref : https://www.amazon.com/Periodic-Table-Cannabis-Poster-Print/dp/B00MBI4HVM Cannabis Plant Anatomy Sinsemilla “without seeds” Trichomes Ref : https://herbology.org/2019/08/14/cannabis-anatomy-the-parts-of-the-plant/ Male Female Hermaphroditic Pollen sac Stigma Pollen sac + Stigma Ref : https://www.amsterdamgenetics.com/spot-male-female-hermaphrodite-cannabis/ Non cannabinoids • Terpenes • Sugars • Flavonoids • Fats • Chlorophyll • Lignin • Pigments • Starches • Waxes • Celluloses • Pectins • Etc.
    [Show full text]
  • Pharmacodynamics of Cannabinoids
    Open Access Archives of Pharmacy and Pharmaceutical Sciences Review Article Pharmacodynamics of cannabinoids Alexandra Sulcova* ISSN ICCI - International Cannabis and Cannabinoids Institute, Jachymova 26/2, 110 00 Praha, 2639-992X Czech Republic “Pharmacodynamics of cannabinoids “(i.e. a set of biological effects elicited in the *Address for Correspondence: Alexandra Sulcova, M.D, Ph.D, Professor of Pharmacology, living organism by interaction with its biochemical and biophysical functions up to the FCMA, FECNP, FCINP, ICCI - International cellular level) is studied for a long time during both, physiological and pathological Cannabis and Cannabinoids Institute, Jachymova conditions. Cannabinoids received their names according to their natural occurrence 26/2, 110 00 Praha, Czech Republic, Tel: 420 732167678; Email: [email protected] as constituents of Cannabis sativa L. (marijuana). The species was classiied in the “Linnaeus’s Species Plantarum (1753)”, the word “sativa” means things that are Submitted: 12 April 2019 Approved: 07 May 2019 cultivated [1]. For ages, people have used cannabis-based preparations for healing and Published: 08 May 2019 pain suppression until the discovery (in 1897) of aspirin (acetylsalicylic acid) which contemporary medicine uses until today. Chemical investigation of marijuana conirmed Copyright: © 2019 Sulcova A. This is an open access article distributed under the Creative various cannabinoid-type components called cannabinoids (presently estimated at Commons Attribution License, which permits about 150). Regarding their possible pharmacodynamic effects, tetrahydrocannabinol unrestricted use, distribution, and reproduction (THC) and cannabidiol (CBD) are the most explored. The determination of THC structure in any medium, provided the original work is properly cited by means of nuclear magnetic resonance imaging increased sharply the number of professional scientiic reports dealing with the studies of THC pharmacodynamic mechanisms of action [2].
    [Show full text]
  • Cannabis-Related Pharmaceutical Drugs
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 31 August 2020 Type of the Paper (Review) Cannabis-related pharmaceutical drugs Dvora Namdar1, Omer Anis2, Patrick Poulin3, Hinanit Koltai1,* 1 Institute of Plant Science, Agriculture Research Organization, Volcani Center, Rishon LeZion 7528809, Israel; [email protected]; [email protected] 2 Department of Urology, Sheba Medical Center; [email protected] 3 Consultant Patrick Poulin Inc., Québec City, Québec, Canada; School of Public Health, Université de Montréal, Montréal, Canada; [email protected] * Correspondence: [email protected]; Tel.: +972‐3‐9683039 (H.K.) Abstract: Despite the surge in the research of cannabis chemistry and its biological and medical activity, only a few cannabis‐based pharmaceutical‐grade drugs have been developed and marketed to date. Not many of these drugs are Food and Drug Administration (FDA)‐approved and some are still going through regulation processes. Active compounds including cannabinergic compounds (i.e., molecules targeted to modulate the endocannabinoid system) or analogs of phytocannabinoids (cannabinoids produced by the plant) may be developed into single‐molecule drugs. However, since in many cases treatment with whole plant extract is preferred over treatment with a single purified molecule, some more recently developed cannabis‐derived drugs contain several molecules. Different combinations of active plant ingredients (API) from cannabis with proven synergy may be identified and developed as drugs to treat different medical conditions. However, possible negative effects between cannabis compounds should also be considered, as well as the effect of the cannabis treatment on the endocannabinoid system. FDA registration of single, few or multiple molecules as drugs is a challenging process and certain considerations that should be reviewed in this process, including issues of drug‐drug interactions, are also discussed here.
    [Show full text]
  • Factors Affecting the Regulatory Context of Marijuana and Cannabinoids in the Workplace Technical Letter Report
    PNNL-27050 Factors Affecting the Regulatory Context of Marijuana and Cannabinoids in the Workplace Technical Letter Report November 2017 KM Branch EP Kennedy ME Lerchen* AC Dalton *Corresponding author Prepared for the U.S. Nuclear Regulatory Commission under an Interagency Agreement with the U.S. Department of Energy Contract DE-AC05-76RL01830 PNNL-27050 Factors Affecting the Regulatory Context of Marijuana and Cannabinoids in the Workplace Technical Letter Report KM Branch EP Kennedy ME Lerchen* AC Dalton *Corresponding author November 2017 Prepared for the U.S. Nuclear Regulatory Commission under an Interagency Agreement with the U.S. Department of Energy Contract DE-AC05-76RL01830 Pacific Northwest National Laboratory Richland, Washington 99352 PNNL-27050 ABSTRACT Studies clearly demonstrate that the use of marijuana (Cannabis sativa and other related Cannabis species and hybrids) and cannabinoids from other sources have negative impacts on an individual’s fitness to perform safety- or security-sensitive functions. The discovery of the endocannabinoid system (i.e., cannabinoid receptors, their location, and function within the human body) in the 1980s, and the subsequent characterization of that system provided a framework for examining the role and function of cannabinoids. That framework prompted an increase in research on the effects of substances that activate or inhibit the endocannabinoid system, including marijuana and synthetic cannabinoids, which led to a greater understanding of the potential benefits and adverse effects of such substances. This new understanding has heightened interest in the potential medical uses of cannabinoids, development of pharmaceutical cannabinoids, and re-examination of previous research on cannabinoid metabolism, elimination, and the relationship of effects to dose and time.
    [Show full text]